Adipocyte browning and resistance to obesity in mice is induced by expression of ATF3

Figures

• 

  Fig. 1. Analysis of ATF3 expression level among liver, adipose tissue, muscle and blood monocytes from lean, obese and morbidly obese patients by NCBI GEO DataSets. a–d ATF3 expression level in different organs. a Liver. b Adipose tissue. c Muscle. d Blood monocytes. For a, Lean (n = 13), Obese (n = 26). For b, Lean (n = 5), Obese (n = 18). For c, ControlLean (n = 8), Obese (n = 8), m-Obese (n = 7). For d, Lean (n = 4), Obese (n = 7), m-Obese (n = 7). Data are mean ± SEM. and *p < 0.05 compared to control group

• 

  Fig. 2. Loss of ATF3 in mice aggravated high fat diet (HFD)-induced obesity and metabolic dysfunction. ATF3 gene-deleted mice (ATF3−/−) and their wild-type littermates (WT) fed a normal diet (ND) or a HFD for 22 or 14 weeks, respectively. Measurement was performed after 12 weeks of HFD feeding for both groups. a Body weight of wild-type (WT) and ATF3−/− mice fed a normal diet (ND) or HFD and body image. b Body composition of wild-type and ATF3−/− mice. Proportion of body fat and lean mass as a percentage of their respective body weights. c Serum triglycerides (TG) level. d Glucose tolerance test. e Insulin tolerance test. f White adipose tissue (WAT) and brown adipose tissue (BAT) fat-pad weights. g Representative H&E staining of inguinal WAT (iWAT), epididymal WAT (eWAT), and BAT. h Adipocyte diameter (µm), size (μm2), number per area (mm2), and perigonadal fat pad weight per body weight (g). i Oil-red O staining in liver. For a, n = 3 per group (ND); wild-type, HFD (n = 4), ATF3−/−, HFD (n = 9). For b, n = 12 per group. For c, n = 5 per group. For d, wild-type (n = 4), ATF3−/− (n = 5). For e, n = 3 per group. For f, wild-type (n = 3), ATF3−/− (n = 3 in 6-week HFD; n = 7 in 12-week HFD;…

• 

  Fig. 3. Loss of ATF3 aggravated the expression of inflammation-related genes in HFD-induced obese mice. a ATF3 protein level in iWAT and BAT of wild-type and ATF3−/− mice after HFD feeding for 12 weeks. b Representative immunofluorescence images of adiponectin (red IF) and ICAM-1 (green IF) in wild-type and ATF3−/− mice. Yellow scale bar indicated the size of adipocyte tissues. c Serum protein levels of adipokine and inflammation-related genes in wild-type and ATF3−/− mice after HFD feeding for 8 weeks by adipokine assays; Gel-Pro Analyzer software was used for densitometry of blots. d Serum protein level of adiponectin, ICAM-1 and resistin by ELISA assays in wild-type and ATF3−/−mice after HFD feeding for 8 weeks. e Quantified real-time PCR analysis of mRNA levels of iNOS, IL-6, and TNFα in livers of wild-type and ATF3−/− mice. For a–c, n = 3 per group. For d, wild-type (n = 4 in adiponectin; n = 5 in ICAM1; n = 8 in resistin), ATF3−/− (n = 7 in adiponectin; n = 5 in ICAM1; n = 7 in resistin). For e, n = 6 per group. Scale bar for image b: 50 µm. Data are mean ± SEM; *p < 0.05 compared to wild-type

• 

  Fig. 4. Adeno-associated virus 8 (AAV8)-mediated expression of ATF3 reversed metabolic dysfunction in ATF3−/− mice. Analysis of mice fed an HFD for 12 weeks: untreated wild-type mice, AAV8-GFP–treated ATF3−/− mice (AAV8-GFP- ATF3−/−), or AAV8-ATF3-treated ATF3−/− mice (AAV8-ATF3-ATF3−/−). a Body weights. b Serum TG level. c Glucose tolerance test. d Insulin tolerance test. e Representative H&E staining of epididymal WAT. f Adipocyte diameter (μm), size (μm2), number per area (mm2), and perigonadal fat pad weight per body weight (g). For a, n = 3 per group. For b, n = 5 per group. For c–e, n = 3 per group. For f, n = 3 per group, except wild-type (n = 5), AAV8-GFP-ATF3−/− (n = 5), AAV8-ATF3-ATF3−/− (n = 5) in % of perigonadal fat pads weight/body weight. Scale bar for image e: 50 µm. Data are mean ± SEM; #p < 0.05 compared to wild-type. *p < 0.05 AAV8-GFP-ATF3−/− vs. AAV8-ATF3-ATF3−/−

• 

  Fig. 5. ATF3−/− mice showed dysregulated WAT/BAT balance. Analysis of ATF3−/− and wild-type mice after 12 weeks of HFD feeding. a Weights of brown adipose tissue (BAT) and white adipose tissue (WAT) in individual depots including inguinal WAT (iWAT), epididymal WAT (eWAT), mesenteric WAT (mWAT), and retroperitoneal WAT (rWAT) fat pads. b Analysis of gene expression of adipogenic, lipogenic, and lipolytic genes in iWAT. c Analysis of gene expression of brown (BAT), beige (Bei), mitochondria (Mito), and β-oxidation (β-oxi) markers in iWAT. d Analysis of expression of brown/mitochondria/β-oxidation markers in BAT. e Protein levels of ChREBP, SCD1, UCP1 and adiponectin in iWAT. f Protein level of UCP1 in BAT. For a, wild-type (n = 8), ATF3−/− (n = 9). For b, n = 3 per group. For c, n = 4 per group. For d, n = 6 per group. For e, f, n = 3 per group. Data are mean ± SEM; *p < 0.05 compared to wild-type

• 

  Fig. 6. ATF3−/− mice showed impaired energy metabolism and thermoregulation. a Body and rectal temperature during acute cold exposure. b Body weight after 9 weeks of HFD feeding. c Measurement of oxygen consumption levels, d respiratory exchange ratio (RER), and e energy expenditure in ATF3−/− and wild-type mice after 9 weeks of HFD feeding. For a, wild-type (n = 6), ATF3−/− (n = 5). For b, wild-type (n = 7), ATF3−/− (n = 9). For c–e, wild-type (n = 4), ATF3−/− (n = 5). Data are mean ± SEM; *p < 0.05 compared to wild-type

• 

  Fig. 7. ATF3-overexpressing 3T3-L1 adipocytes showed suppression of lipogenesis/adipogenesis and activation of mitochondrial, brown or beige fat programs. a, b Real-time PCR analysis of mRNA levels of adipogenic, lipogenic, and lipolytic genes; c, d BAT, beige (Bei), mitochondria (Mito), and β-oxidation (β-oxi) genes after 2 and 8 days of differentiation in ATF3-overexpressing 3T3-L1 cells, normalized to GAPDH and relative to pcDNA control. e, f The expression level of ChREBPand FABP4 in iWAT of wild-type and ATF3−/− mice after 6, 8, and 16 weeks of HFD feeding. f The expression level of FABP4 in iWAT of wild-type and ATF3−/− mice after 6, 8, and 16 weeks of HFD feeding. g FABP4 promoter activity measured with or without overexpression of ATF3 in 3T3-L1 pre-adipocytes. h Overexpression of ATF3 repressed the ChREBP promoter activity of the p (−2980)/Luc reporter but not other reporters in 3T3-L1 pre-adipocytes. i The sequence of 3 potential binding sites for ATF3 in ChREBP promoter, including region #1 (–2810/–2803), region #2 (−2790/−2783) and region #3 (−2721/−2714) of the ChREBP locus. j Chromatin immunoprecipitation (ChIP) experiments with ATF3-specific antibody and primers to amplify…

• 

  Fig. 8. Identification of ATF3 inducers and their functional assays. a Construction map of ATF3 promoter in pGL4.17 plasmid containing luciferase cassette. b Luciferase activity of stable clones of 3T3-L1 pre-adipocytes expressing pGL4.17-ATF3, with tBHQ as a positive control. c Luciferase activity measured in 3T3-L1 pre-adipocytes transfected with pGL4.17-ChREBP (p (−2980)/Luc reporter), then treated with ST32da or ST32db or ST32c. d Oil-red O staining in differentiated 3T3-L1 adipocytes with and without the ATF3 inducer ST32da (10 and 50 µM) for 8 days. e Real-time PCR analysis of mRNA levels of adipogenic, lipogenic, and lipolytic genes; f BAT, beige (Bei), mitochondria (Mito) and β-oxidation (β-oxi) genes with 2 and 8 days of ST32da treatment during 3T3-L1 differentiation normalized to GAPDH and relative to control. For b–d, n = 3 per group. For e, n = 4 per group. For f, n = 6 per group. Data are mean ± SEM; *p < 0.05 compared to control. #p < 0.05 compared to pGL4.17-ATF3

• 

  Fig. 9. ATF3 inducer, ST32da, protects against HFD-induced obesity and metabolic dysfunction by promoting browning in vivo. Analysis of wild-type mice fed a HFD for 12 weeks with or without i.p. ST32da 1 or 2 mg kg−1 per day. a Body weight and food intake. b Change in adipose tissue depot weight in BAT and WAT. c H&E staining of inguinal WAT, epididymal WAT, and BAT fat depots. d Glucose tolerance test (GTT). e Insulin tolerance test (ITT). f Real-time PCR analysis of mRNA levels of ATF3, c-Jun, PGC-1α and UCP1. g Real-time PCR analysis of mRNA levels of brown (BAT) and beige (Bei), mitochondria (Mito), and β-oxidation (β-oxi) genes in iWAT; h adipogenic, lipogenic, and lipolytic genes in iWAT; and i brown fat programs in BAT. For a, HFD (n = 10), HFD + 1 mg kg−1 per day ST32da (n = 8), HFD + 2 mg kg−1 per day ST32da (n = 8). For b, HFD (n = 9), HFD + 1 mg kg−1 per day ST32da (n = 7), HFD + 2 mg kg−1 per day ST32da (n = 6). For c, n = 3 per group. For d, e, HFD (n = 4), HFD + 1 mg kg−1 per day ST32da (n = 5), HFD + 2 mg kg−1 per day ST32da (n = 4). For f, g, n = 6 per group. For h, HFD (n = 6), HFD + 1 mg kg−1 per day ST32da (n = 5), HFD + 2 mg kg−1 per day ST32da (n = 6). For i, n = 6…

• 

  Fig. 10. Oral administration of ATF3 inducer, ST32da, is effective in preventing HFD-induced obesity. Analysis of wild-type mice fed a HFD for 16 weeks, either without or treated with oral orlistat (50 mg kg−1, three times per week) or oral ST32da (50 mg kg−1, three times per week). a Body weights and food intake. b Variation of adipose tissue depot weight in BAT and WAT. c H&E staining of inguinal WAT, epididymal WAT, and BAT fat depots. d Serum parameters. e Liver weight. f Liver function. g Real-time PCR analysis of mRNA levels of ATF3, c-Jun, PGC-1α and UCP1 in iWAT; h brown (BAT), beige (Bei), mitochondria (Mito), and β-oxidation (β-oxi) genes in iWAT; i adipogenic, lipogenic, and lipolytic genes in iWAT; j brown/mitochondria/β-oxidation markers in BAT. For a, ND (n = 2), HFD (n = 7), HFD + 50 mg kg−1 Orlistat (n = 7), HFD + 50 mg kg−1 ST32da (n = 7). For b, ND (n = 2), HFD (n = 5), HFD + 50 mg kg−1 Orlistat (n = 6), HFD + 50 mg kg−1 ST32da (n = 8). For c, n = 3 per group. For d, HFD (n = 8), HFD + 50 mg kg−1 Orlistat (n = 7), HFD + 50 mg kg−1 ST32da (n = 6). For e, ND (n = 2), HFD (n = 5), HFD + 50 mg kg−1 Orlistat (n = 6), HFD + 50 mg kg−1 ST32da (n = 8). For f, HFD (n = 8), HFD +…